Henri A. Termeer

Who is Henri A. Termeer?

Henri A. Termeer was appointed president of Genzyme Corporation in

1983, two years after the company's founding. He became its chief

executive officer in 1985 and chairman in 1988. Under his leadership,

Genzyme has grown from a modest entrepreneurial venture to one of the

world's leading biotechnology companies.

Genzyme

develops, manufactures and markets a range of innovative health care

products and services that make a major positive impact on the lives of

patients around the world. Genzyme's more than 9,500 employees serve

patients in nearly 90 countries, and the company's 2006 revenues were

$3.2 billion. Genzyme has delivered consistent financial results, with

a compound annual growth rate in excess of 20 percent over the past

five years. In 2007, Genzyme was chosen to receive the National Medal

of Technology, the highest honor awarded by the President of the United

States for technological innovation.

Mr.

Termeer is recognized as a pioneer in developing and delivering

treatments to patients with rare genetic diseases around the world.

This work has provided the foundation for Genzyme's success, and today

the company is diversified across medical areas including lysosomal

storage disorders, kidney disease, orthopaedics, cancer, transplant and

immune diseases, and diagnostic testing.

Widely

acknowledged for his contributions to the biotechnology industry and

health care field, Mr. Termeer is active in the areas of humanitarian

assistance, policy issues, and innovation in providing access to health

care. He serves on the board of directors of both the Biotechnology

Industry Organization and the Pharmaceutical Research and Manufacturers

of America. He is a director of Massachusetts General Hospital and is a

member of the board of fellows of Harvard Medical School.

Mr.

Termeer is deputy chairman of the Federal Reserve Bank of Boston's

board of directors and a member of the board of directors of Abiomed

Inc. He is also chairman emeritus of the New England Healthcare

Institute, a nonprofit, applied research health policy organization he

was instrumental in founding.

With

a great dedication to improving global health, Mr. Termeer is a member

of the board of directors of Project HOPE, an international nonprofit

health education and humanitarian assistance organization. Through a

partnership with Project HOPE, Genzyme provides life-saving treatment

at no cost to patients in developing countries. In addition to working

with Project HOPE, Mr. Termeer has a strong interest in finding

innovative ways to address neglected diseases in the developing world.

Mr.

Termeer has been recognized by several highly regarded organizations

for his contributions to the health care field. In 2007, he received

Ernst Young's Master Entrepreneur Award for the role he has

played in guiding the overall development of the biotech industry. The

award is presented periodically to entrepreneurs who have contributed

to meeting significant needs in society through the creation of

successful companies and the development of new industry sectors. In

2005, Mr. Termeer was elected to Honorary Fellowship at the British

Royal College of Physicians, a more than 450-year-old organization

dedicated to improving health care through the promotion of high

standards in medical practice. In 2003, he received the Franklin Delano

Roosevelt Humanitarian Award from the March of Dimes and the Cor Vitae

Award from the American Heart Association. Mr. Termeer has also been

inducted as a Fellow in the American Academy of Arts and Sciences.

A

native of the Netherlands, Mr. Termeer in 1999 received the Golden Door

Award from the International Institute of Boston, which recognizes the

positive influence that immigrants have had on America. In 1995, Mr.

Termeer was honored by the Anti-Defamation League's New England Region

with the Torch of Liberty Award for his leadership in human rights and

for promoting understanding among people of diverse religious, ethnic

and racial...